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Abstract
Background: The goals of intentional curative pediatric epilepsy surgery are to achieve seizure-freedom and
antiepileptic drug (AED) freedom. Retrospective cohort studies have indicated that early postoperative AED
withdrawal unmasks incomplete surgical success and AED dependency sooner, but not at the cost of long-term
seizure outcome. Moreover, AED withdrawal seemed to improve cognitive outcome. A randomized trial is needed
to confirm these findings. We hypothesized that early AED withdrawal in children is not only safe, but also
beneficial with respect to cognitive functioning.
Design: This is a multi-center pragmatic randomized clinical trial to investigate whether early AED withdrawal
improves cognitive function, in terms of attention, executive function and intelligence, quality of life and behavior,
and to confirm safety in terms of eventual seizure freedom, seizure recurrences and “seizure and AED freedom.”
Patients will be randomly allocated in parallel groups (1:1) to either early or late AED withdrawal. Randomization
will be concealed and stratified for preoperative IQ and medical center. In the early withdrawal arm reduction of
AEDs will start 4 months after surgery, while in the late withdrawal arm reduction starts 12 months after surgery,
with intended complete cessation of drugs after 12 and 20 months respectively. Cognitive outcome measurements
will be performed preoperatively, and at 1 and 2 years following surgery, and consist of assessment of attention
and executive functioning using the EpiTrack Junior test and intelligence expressed as IQ (Wechsler Intelligence
Scales). Seizure outcomes will be assessed at 24 months after surgery, and at 20 months following start of AED
reduction. We aim to randomize 180 patients who underwent anticipated curative epilepsy surgery below 16 years
of age, were able to perform the EpiTrack Junior test preoperatively, and have no predictors of poor postoperative
seizure prognosis (multifocal magnetic resonance imaging (MRI) abnormalities, incomplete resection of the lesion,
epileptic postoperative electroencephalogram (EEG) abnormalities, or more than three AEDs at the time of surgery).
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Discussion: Growing experience with epilepsy surgery has changed the view towards postoperative medication
policy. In a European collaboration, we designed a multi-center pragmatic randomized clinical trial comparing early
with late AED withdrawal to investigate benefits and safety of early AED withdrawal. The TTS trial is supported by
the Dutch Epilepsy Fund (NL 08-10) ISRCTN88423240/ 08/05/2013.
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Background
For children with refractory epilepsy, epilepsy surgery is a
successful and widely accepted therapeutic option with
postoperative seizure freedom rates ranging from 41 to
93 % [1, 2]. In patients who have been operated on and
who have reached seizure freedom the ultimate goal is to
discontinue antiepileptic drug (AED) use and to improve
developmental capacities [3–5]. AEDs are known to have
cognitive side-effects, particularly in children. Most affected
cognitive functions are attention, vigilance and psycho-
motor speed [6–9]. AED reduction has been reported to
improve cognitive processing under time pressure [8, 10],
psychomotor speed and alertness [11–13], processing speed
[14], verbal memory [15] and Intelligence Quotient (IQ)
[9]. The growing body of evidence that cognitive function-
ing improves after AED withdrawal has increased aware-
ness of the possible benefits of the earliest possible
withdrawal of AEDs after epilepsy surgery. Two recently
published studies [16, 17] showed that early withdrawal of
drug treatment unmasks incomplete surgical success and
AED dependency sooner, but not at the cost of worse long-
term seizure outcome. Thus, early AED withdrawal would
discern the few that require further AEDs from the many
that can safely stop, without changing the chance of regain-
ing seizure freedom. A pressing question is whether early
AED withdrawal improves cognitive outcome measures, as
compared to current care with usually later AED with-
drawal. To answer that question we designed a pragmatic
randomized clinical trial to investigate the benefits and
safety of early AED withdrawal after epilepsy surgery in
children. We hypothesize that 1) children who discontinue
AED’s early have better cognitive scores, behavior and qual-
ity of life than those who discontinue late, particularly at
1 year after surgery (when 1 group is without AEDs and
the other is still on AEDs), and maybe persisting from then
on, and 2) early AED withdrawal is safe and does not cause
more recurrences that are unresponsive to restart of medi-
cation, than late withdrawal.
Study objectives
The primary objective is to investigate whether early AED
withdrawal improves cognitive function, in terms of atten-
tion and executive functions, compared to late AED reduc-
tion. The secondary objectives are to assess (improvement
in) IQ, and safety, in terms of seizure recurrences, long-
term seizure freedom and “seizure and AED freedom” of
early versus late AED withdrawal. Seizure freedom will be
defined as complete seizure freedom (including auras),
expressed as Engel 1A or ILAE class 1 for at least 1 year
[18, 19], and “seizure and AED freedom” as being seizure
free without medication for at least 1 year. In addition, we
will compare behavior, quality of life and other neuro-




The TimeToStop trial will be a European multicenter
pragmatic randomized clinical trial. In the Netherlands
the trial has been approved by the Medical Ethical Com-
mittee of the University Medical Center Utrecht, which
is the leading ethical committee. Other participating
centers are in the process of protocol submission and
have not yet obtained definite approval. Only then, local
patient recruitment will start. For every patient who will
be included in the trial we will obtain informed consent.
In the TimeToStop trial, index intervention is early
withdrawal: AED withdrawal is started 4 months after
surgery and completed within 8 months after start of
withdrawal (thus, at latest 12 months postoperatively).
Reference intervention is late AED withdrawal: tapering
off medication starts at 12 months after surgery and
completion should be within 20 months after surgery.
For both treatment arms, the total tapering period is set
at 8 months maximum and clinicians may decide which
AED they want to taper first and at what speed they will
reduce each individual drug. A tapering period of
8 months is considered reasonable, as from the retro-
spective TimeToStop (TTS) study [16] it could be calcu-
lated that patients who fulfill the inclusion criteria used
on average 1.7 AEDs prior to surgery (range 0–3). The
late (reference) starting point of AED tapering – i.e.
12 months – is based on current practice; the median
interval between surgery and drug reduction in our
retrospective European study was 12.5 months [16]. The
4 months’ time-point in the early withdrawal group is
selected mainly because of logistical reasons. First,
informing parents and recruiting patients needs time.
Second, inclusion requires proof of early surgical suc-
cess, which needs a certain time window to discriminate
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between acute postoperative (running-down) seizures
and true seizure recurrence. Third, in some children cli-
nicians may want to prove completeness of resection by
performing a postoperative magnetic resonance imaging
(MRI), for which a minimum follow-up time of a few
months is required. For both intervention strategies, the
treating physician is allowed to start tapering earlier if
patients experience unacceptable side effects of pre-
scribed AEDs. Rescue medication that is started pre-
operatively and withdrawn shortly after surgery, can be
discontinued according to existing local routine practice,
and will not be investigated in this study.
The trial’s primary outcome measure at 1 year after
surgery is cognitive functioning, in terms of attention
and executive functioning, which will be assessed using
the EpiTrack Junior [20]. As secondary cognitive out-
come measure, intelligence will be tested with the
Wechsler Preschool and Primary Scales, the Wechsler
Intelligence Scale for children, or the Wechsler Adult
Intelligence scale, depending on the children’s age and
capabilities; scores derived are Verbal (VIQ), Performal
(PIQ) and Full-scale IQ, perceptual organization or
reasoning and information processing speed index
scores. We will measure baseline neuropsychological
status maximum 3 months before surgery (t1), and there-
after at 12 months (±2 months) (t2) and 24 months
(±2 months) (t3) postoperatively. Patients and/or parents
will at all neuropsychological test points complete three
types of questionnaires to assess the secondary outcome
measures: the Child Behavior Checklist (CBCL) and the
the Hague Side Effects Scale (HASES) [21] will be com-
pleted by the parents, and the Pediatric Quality of Life
InventoryTM (PedsQL™) will be completed by both parents
and patients. This design will allow us to assess whether
cognitive performance is better in the early AED-
withdrawal group, with patients being AED-free at 1 year
following surgery, compared to the group that is still on
full medication at the first postoperative time point. It will
also enable the study of differences at a later follow-up
time point, when both groups have completely discontin-
ued medication (t3) (Fig. 1). Seizure outcome will be
assessed at the moment of randomization, as seizure
Fig. 1 Trial design. Flowchart of trial design; NPA, neuropsychological assessment
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freedom is an inclusion criterion, at 24 months after sur-
gery, and at 20 months following start of AED withdrawal.
This design allows us to assess differences in seizure out-
come at equal AED-free intervals for both groups, and at
2 years after surgery irrespective of length of AED freedom.
Patients will be allocated to treatment strategy by con-
cealed blocked randomization and randomization will be
stratified for preoperative IQ score and medical center.
The primary goal of randomization is to achieve an AED
treatment duration contrast. Therefore, physicians and
patients allocated to an arm will be instructed to comply
with that strategy. However, these intervention strategies
will to a certain extent be in compliance with clinical prac-
tice, and allow “protocol violations” for the following
instances: if patients have seizure recurrences in the
period before scheduled AED withdrawal, they do not
have to start AED withdrawal. The same applies to seizure
recurrences that occur after start of tapering medication.
Patients can restart medication and do not have to taper
medication again, regardless of planned medication status.
Notably, whatever “protocol deviations” will occur, pa-
tients will be analyzed as randomized (intention-to-treat
principle).
Inclusion criteria
In order to be eligible a subject must meet all of the fol-
lowing criteria:
 Younger than 16 years at surgery, with focal non-
idiopathic epilepsy
 Native speaker in the language in which the
neuropsychological tests have to be taken
 Able to perform an EpiTrack Junior [20] test
preoperatively
 Underwent intentionally curative epilepsy surgery
 After surgery, the treating physician considers
withdrawal of AEDs, with the intention to
completely discontinue medication
 The treating physician, the patient (if capable), and
the parents agree with randomization in either arm
of the study
 Postoperative seizure freedom was achieved (with
the exception of so-called running down seizures
not outlasting 2 weeks)
 Written informed consent of children and both parents
or caregivers of children older than 12 years, and of
both parents or caregivers of children below that age
Exclusion criteria
A subject who meets any of the following criteria will be
excluded from participation:
 A contraindication to be randomized to either of the
two withdrawal strategies
 The treating physician does not want to discontinue
all AEDs within a maximum time frame of 8 months
as prescribed in the study protocol
 Multifocal MRI abnormalities, known incomplete
resection of the anatomical or epileptogenic lesion
certified before randomization (if considered
necessary by the treating physician a
postoperative MRI may be performed) and, if a
postoperative electroencephalogram (EEG) is
performed before randomization (at the discretion
of the treating physician), epileptic EEG
abnormalities. These are the most important risk
factors of seizure recurrence or unfavorable long-
term seizure outcome [16]
 Use of more than three AEDs at the time of
surgery. The reason is that clinicians can then
not be expected to want to wait for 12 months in
the late withdrawal arm to reduce the first AED
in these patients. Furthermore, withdrawing 4 or
more AEDs within 8 months may be difficult to
achieve
 Patients who are on a ketogenic diet or have a vagal
nerve stimulator implanted
 If surgery is primarily intended as “tumor surgery” (a
growing epileptogenic lesion was the indication for
surgery) and not as epilepsy surgery
Excluded patients
Participating centers will provide brief anonymized in-
formation about all children who are operated on, in-
cluding those who were not in the trial, to document
reasons for exclusion and the overall proportion of eli-
gible patients, allowing the assessment of generalizability
of the trial results. We will only report aggregated data
of excluded patients.
Statistical analysis
The general approach towards analysis will be on an
intention-to-treat basis, so patients randomized will be
analyzed and accounted for as allocated, independent of
later compliance.
For all analyses described below, we will add baseline
adjusted analyses using various regression techniques (lin-
ear regression for continuous and logistic regression for
binary outcomes). For these adjustments to increase statis-
tical precision, we will use propensity score methods or
inverse variance weighting methods.
Prior to analyses described below, we will deal with
missing values by formal accepted multiple imput-
ation methods, for reasons of optimizing statistical
precision but more importantly because particularly
loss to follow-up may be expected not to occur ran-
domly in this trial.
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Outcome parameters
Cognitive outcome: differences in EpiTrack scores, IQ
scores and other continuous outcome measures of
neuropsychological assessment will be analyzed using
independent samples t-tests or other tests depending on
distributions. EpiTrack and IQ differences will be
assessed cross-sectionally to answer the primary research
question. Additionally, longitudinal changes in EpiTrack
measures and IQ compared to preoperatively will be
assessed between both treatment arms using linear
mixed models. We will calculate a number needed to
treat, expressed as the number of patients required to
taper drugs earlier to achieve one more patient with im-
provement in attention. Analyses will be considered
statistically significant if 95 % confidence intervals for
group differences do not include 0, compatible with a 2-
sided p < 0.05. For chances of eventual seizure freedom
and “seizure and AED freedom”; we will calculate a rela-
tive risk and a risk difference with 95 % confidence inter-
vals. Chances of eventual seizure freedom and “seizure
and AED freedom” will be compared between the groups
at 24 months after surgery and at 20 months following
start of AED withdrawal; for the early withdrawal arm this
will be at 24 months and for the late withdrawal arm at
32 months.
Sample size calculation
The study is powered based on the primary neuro-
psychological measures attention and executive function,
determined with the EpiTrack Junior. We plan to study
a continuous response variable from a late withdrawal
(control) versus an early withdrawal (experimental)
group with one control per experimental subject. For
the sample size calculation, we used the reference values
given in the Introduction and first validation of EpiTrack
Junior [20], which presents reference values of healthy
children and children with epilepsy. The mean (SD) Epi-
Track Junior score in healthy children was 32.6 (2.40).
In children with epilepsy the mean (SD) score was 29.5
(4.70). For sample size calculations, we calculated the
sample size using the SD of the epilepsy patients. Based
on numbers of patients operated on per year in the par-
ticipating medical centers and excluding patients with
incompletely resected lesions, multifocal MRI abnormal-
ities, an epileptic EEG postoperatively and use of a max-
imum of three AEDs at time of surgery (the numbers
derived from the previous retrospective study [16]), we
estimated to expect to include at least 90 patients per
year. By including at least 150 patients in the trial, with
75 patients per arm, we will be able to detect a true dif-
ference in the mean response of 2.16 points in EpiTrack
Junior score (which corresponds to a difference of 0.46
SD) with a 2-sided alpha = 0.05 and power (1-beta) = 0.8.
This difference is considered clinically relevant, as for
the EpiTrack a 0.5 SD difference, can reflect a shift to-
wards a milder impaired group of epilepsy patients [20].
One interim analysis according to O’Brien Fleming is
planned after half of the planned number of patients has
reached their endpoints. For reasons of possible dropout,
we will aim to include 180 patients.
Ethical approval
The multicenter trial will start in the University Medical
Center Utrecht, the Netherlands, in November 2015. Eth-
ical permission has been obtained from the ethical com-
mittee of the University Medical Center Utrecht, which is
the leading ethical committee. Eight sites: University Hos-
pitals of Lyon (HCL), France; University Hospital Stras-
bourg, France; Epilepsy Center Freiburg, Epilepsy Center
Kork, University Hospital Heidelberg, Germany; Great
Ormond Street Hospital for Children NHS Foundation
Trust, London, and Young Epilepsy, Lingfield, United
Kingdom; Western General Hospital Edinburgh, Scotland;
Hôpitaux Universitaire de Genève, Switzerland, will join
the trial shortly thereafter. Other centers, that have ad-
equate experience with pediatric epilepsy surgery, are wel-
come to participate.
Safety monitoring
To minimize the risk for the participants in the proposed
trial, we will exclude patients with those characteristics
that have previously been shown to predict unfavorable
outcome [16]. In our retrospective cohort we simulated
the prospective randomized trial on 478 patients who
would be eligible based on their exact inclusion and exclu-
sion criteria. In this group, the interval to start of AED
reduction was not associated with seizure recurrences
during or after AED withdrawal (p = 0.155, HR 0.94; CI
0.86–1.02 per 3 months), nor with eventual seizure free-
dom (p = 0.551, HR 0.96; CI 0.85–1.09) or seizure and
AED freedom (p = 0.516, HR 1.01 CI 0.97–1.06, Cox
regression analysis). Based on these analyses, we expect an
overall comparable percentage of seizure recurrences in
both treatments arms, similar to the number or recur-
rences encountered in everyday clinical practice when
starting tapering of AEDs.
We appointed a Data Safety Monitoring Board (DSMB)
that will analyze our data to warrant safety and to monitor
inclusion rates and assess inclusion feasibility. At
24 months a blinded interim-analysis will be performed by
the DSMB to investigate superiority of one of the treat-
ment arms with regard to the primary outcome measure.
If the difference in attention between groups is more than
1 SD (age appropriate average reaction time), the DSMB
may advise to prematurely stop the trial, if early with-
drawal shows to be superior, the remaining patients
in the late withdrawal group who still await start of
AED reduction are allowed to withdraw medication
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from that time on. A test result with a 2-sided p <
0.0054 will be declared significant.
With regard to safety; due to the design of the trial, an
interim safety analysis comparing both treatment arms
at one moment is not possible. This is because we
expect in both arms relapse risks to increase particularly
once AED withdrawal is started. Thus, in the early with-
drawal group recurrences probably occur sooner than in
the late withdrawal group, although the total risk of
relapse at the end of follow-up is not expected to differ
between groups. This implies that at interim time points,
when inherently more patients are under AED reduction
(at increased risk of relapse) in the early arm, a fair com-
parison of relapse between both groups is not feasible.
To deal with this, we will assess safety in each arm
separately. The study intervention will be considered
safe when seizure recurrences occur in less than 40 % of
both treatment arms. This percentage is chosen based
on the general seizure freedom rate after childhood epi-
lepsy surgery of 41 to 93 % [1, 2]. Based on previous
identification of risk factors for seizure recurrences, we
expect recurrence rates in the patients included in the
trial to be < 30 %, due to exclusion of patients with
identified risk factors [1, 16, 22, 23]. We do not expect,
however, the seizure status to be better than in normal
clinical practice. Because of the expected cognitive
benefit due to a longer AED-free period, a 40 % rate of
seizure relapse will still be accepted. The DSMB statis-
tician will analyze the number of patients with seizure
recurrences every 3 months during trial duration, in
order to allow early awareness of unexpected high
numbers of recurrences, exceeding the 40 % limit. In
this sequential testing safety model (Fig. 2), a 1-sided
p value < 0.05 will be considered significant for the
safety monitoring [24, 25].
Adverse event reporting
For this study, recurrent epileptic seizures during AED
withdrawal that need hospitalization do not necessarily
have to be recorded as serious adverse events (SAEs),
but are noted in the case report form (CRF) as one of
the outcome measures, and will be included in the in-
terim safety analyses by the DSMB. Epileptic seizures
that lead to a potentially life-threatening situation, such
as status epilepticus, will be reported as SAEs.
All SAEs will be reported through the web portal
“ToetsingOnline,” to the accredited ethical committee
that approved the protocol, within 15 days after the
sponsor has first knowledge of the serious adverse reac-
tions. Participating centers will inform the sponsor about
the SAEs. Reporting of SAEs that result in death or are
life-threatening should be expedited. The expedited
reporting will occur not later than 7 days after the re-
sponsible investigator has first knowledge of the adverse
reaction. This is for a preliminary report with another
8 days for completion of the report.
Discussion
We present the protocol of a European pragmatic ran-
domized clinical trial, designed to investigate the possible
benefits and the safety of early AED withdrawal after
epilepsy surgery in children. We hypothesize that early
AED withdrawal is safe, in terms of seizure relapse rates
and eventual seizure outcomes, and will improve cognitive
functioning, behavior and quality of life, compared to late
withdrawal. We will investigate these hypotheses by ran-
domly allocating patients to an early withdrawal group
that starts withdrawal of medication 4 months after sur-
gery, versus a late withdrawal group, that starts withdrawal
of medication after 12 months. Justification of this trial
needs to be discussed. The non-experimental evidence
obtained so far on safety of AED withdrawal in relation to
seizure outcome seems strong and consistent [16, 17]. In
analyses that had been elaborately adjusted for confound-
ing, there was a slightly increased recurrence risk for earl-
ier withdrawal, but not for regain of seizure freedom rates
and eventual seizure outcome. Moreover, findings on cog-
nitive outcome after AED withdrawal all pointed towards
cognitive improvement on several domains [3–15]. Why
then do we think that the trial will have important added
value? Through randomized allocation the study population
will be broader than in the non-experimental studies which
only pertained to patients for whom AED withdrawal had
Fig. 2 Sequential testing safety profile. The plot is based on a likely
sample size of 75 patients per treatment strategy, a 1-sided α= 0.05, an
expected seizure recurrence rate≤ 30 % and a cut-off point for safety,
which is a recurrence rate of≥ 40 %. The red boundary represents the
safety margin. The following formulas will be used to plot data in the
graph: Ζ=−(F− n× Pc) (→Ζ= number of observed seizure recurrences –
number of expected seizure recurrences), V = n × Pc (1− Pc) (→V is the
variance of Z and stands for the amount of information in n patients,
with n being the number of included patients, Pc the expected seizure
recurrence risk (i.e., for the selected patient cohort: 0.30) and F the
number of observed seizure recurrences). The vertical line is the
anticipated value for V for a sample size of 75 patients
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already been decided about. Consequently, results will have
wider clinical applicability and will apply to all patients who
are eligible for withdrawal decision- making. A very import-
ant asset will be obtaining baseline comparability of treat-
ment arms for both known and measurable confounders,
but also for unknown or unmeasurable confounders. In
principle, the non-experimental evidence, although elabor-
ately adjusted for known confounders, does leave residual
confounding as an explanation. The trial will allow for full
follow-up of all children randomized and for intention-to-
treat analysis. Finally, through the above, stronger evidence
will contribute to our ultimate goal, implementation of
evidence-based practice concerning AED withdrawal. Al-
though previous non-experimental research does seem to
indicate benefits of early AED withdrawal, it is especially
the remaining uncertainty about residual confounding that
leads us to claim that there currently is genuine equipoise
about timing of withdrawal and, therefore, that random al-
location is ethically justified. This issue will have to be
addressed with regard to trial feasibility. Throughout
European centers participating in the trial, there are
regional preferences concerning AED withdrawal tim-
ing, and non-experimental evidence has already led to
changes in clinical practice concerning withdrawal
timing. It will be vital for successful completion of
the trial that participating physicians can and will be
convinced that there still is true equipoise, as a suffi-
cient basis for studying randomized AED withdrawal
timing to the ultimate benefit of children who have
undergone epilepsy surgery.
Recruitment of participants for this study might be chal-
lenging for three reasons. First, in some of the participat-
ing countries and centers, AED withdrawal policies are
still rather conservative, conflicting with the proposed
early AED strategy. This may either be due to reluctance
of parents or patients to risk a seizure relapse, now that
seizure freedom has finally been achieved following epi-
lepsy surgery, or to fear of the treating neurologist or
neurosurgeon that seizure control is permanently lost
after a post-withdrawal relapse. In addition, in some pa-
tients treating physicians may require a postoperative MRI
to prove complete resection of the epileptogenic lesion
before considering AED withdrawal. Planning of MRI
scanning before randomization may not always be feasible
in the proposed short time period. Second, in many par-
ticipating centers, AED withdrawal policies already tend
to change towards earlier reduction, as a consequence of
the findings from the previous retrospective observational
TTS study [16]. These changing opinions on AED with-
drawal policies are not only known among physicians,
there is also an increasing awareness of safety of early
withdrawal among parents of children who have been op-
erated on. Therefore, willingness to be randomized to the
late withdrawal strategy arm may prove difficult in these
centers. Third, some treating physicians may not want to
withdraw AEDs within a set maximum time frame of
8 months, or only consider reduction of medication in-
stead of complete discontinuation of AEDs, fearing that
relatively early, rapid or complete withdrawal may increase
the risk of seizure relapse. To prevent limited recruitment
of patients we will encourage participating physicians to
counsel parents and patients optimally, based on the avail-
able evidence regarding safety of AED withdrawal, which
can be summarized as follows: although retrospective data
suggest that early withdrawal is safe and does not com-
promise eventual seizure outcome or treatability of seizure
relapse, definite proof of safety in a predefined population
of children who underwent anticipated curative surgery is
still required, justifying randomization to either treatment
arm. Furthermore, although we anticipate cognitive im-
provement following AED discontinuation, the – possibly
enduring – cognitive advantages of early over late with-
drawal need to established, which is important to enable
careful balancing of risks and benefits of early AED dis-
continuation in individual patients in the future.
Trial organization
Steering committee
The steering committee carries the ultimate responsibility
for the trial. Specific tasks of the steering committee are:
1. Design and final approval of the study protocol
2. Approval of the amendments to the study protocol
3. Deciding whether or not to continue the trial based
on the recommendations of the DSMB
4. Approval of manuscripts and publications of the
trial
The Trial committee is constituted of the principle in-
vestigator of each participating center and of the mem-
bers of the Steering committee.
As of 16 March 2015, the members of the Steering
Committee are (in alphabetical order): A. Arzimanoglou,
child neurologist, University Hospitals of Lyon, France,
co-principle investigator; K. Boshuisen, research physician,
University Medical Center Utrecht, the Netherlands; K.P.J
Braun, child neurologist, University Medical Center
Utrecht, the Netherlands, co-principle investigator; J.H.
Cross, child neurologist, Great Ormond Street Hospital
for Children NHS Foundation Trust, London, and Young
Epilepsy, Lingfield, United Kingdom, co-principle investi-
gator; K. Geleijns, child neurologist University Medical
Center Utrecht, the Netherlands, coordinating investiga-
tor; H.J. Lamberink, PhD student, University Medical Cen-
ter Utrecht, the Netherlands; M.M.J. Schooneveld, child
neuropsychologist, University Medical Center Utrecht, the
Netherlands; C.S.P.M Uiterwaal, epidemiologist and statisti-
cian, University Medical Center Utrecht, the Netherlands.
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Principle and coordinating investigators (other than those
listed in the steering committee) at each site are in
alphabetical order: R. Chin, child neurologist, Western
General Hospital Edinburgh, Scotland; T. Polster,
child neurologist, Krankenhaus Mara, Epilepsiezen-
trum Bethel, Bielefeld, Germany; G. Ramantani, child
neurologist, Epilepsy Center Freiburg, Epilepsy Center
Kork, University Hospital Heidelberg, Germany; A. De
Saint-Martin, child neurologist, University Hospital
Strasbourg, France; M. Seeck, epileptologist, Hôpitaux
Universitaire de Genève.
Data Safety Monitoring Board
The DMSC analyses the unblinded data on a permanent
basis and formulates recommendations for the Steering
Committee on the continuation of the trial. The Data
Monitoring Committee may also offer unsolicited rec-
ommendations. Members of the Data Monitoring
Committee are: Prof. Dr. Oebo Brouwer, child neurologist,
epileptologist, UMCG; Dr. Ingeborg van der Tweel,
statistician, UMCU; Prof. Dr. Jaap Kappelle, neurologist,
UMCU.
Trial status
Ethical approval has been obtained for the University
Medical Center Utrecht. The other participating centers
are in the process of obtaining approval. No patients
have yet been included in the trial.
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